Selected article for: "acute respiratory syndrome and lopinavir ritonavir interferon"

Author: Dong, Yijia; Shamsuddin, Azwa; Campbell, Harry; Theodoratou, Evropi
Title: Current COVID-19 treatments: Rapid review of the literature
  • Cord-id: krghq8lo
  • Document date: 2021_4_24
  • ID: krghq8lo
    Snippet: BACKGROUND: As SARS-CoV-2 continues to spread worldwide, it has already resulted in over 110 million cases and 2.5 million deaths. Currently, there are no effective COVID-19 treatments, although numerous studies are under way. SARS-CoV-2, however, is not the first coronavirus to cause serious outbreaks. COVID-19 can be compared with previous human coronavirus diseases, such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), to better understand the developme
    Document: BACKGROUND: As SARS-CoV-2 continues to spread worldwide, it has already resulted in over 110 million cases and 2.5 million deaths. Currently, there are no effective COVID-19 treatments, although numerous studies are under way. SARS-CoV-2, however, is not the first coronavirus to cause serious outbreaks. COVID-19 can be compared with previous human coronavirus diseases, such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), to better understand the development of treatments. METHODS: Databases Medline, Embase and WHO COVID-19 was systematically searched on 9 February 2021 for studies reporting on therapeutic effect of COVID-19 treatments. Clinical trials, case reports, observational studies and systematic reviews in the English language were eligible. RESULTS: 1416 studies were identified and 40 studies were included in this review. Therapies included are: remdesivir, convalescent plasma, hydroxychloroquine, lopinavir/ ritonavir, interferon, corticosteroids, cytokine storm inhibitors and monoclonal antibodies. Remdesivir, convalescent plasma and interferon seems to provide some clinical benefits such as faster recovery time and reduced mortality, but these effects are not clinically significant. Some corticosteroids are effective in reducing mortality in severe COVID-19 patients. Hydroxychloroquine do not convey any beneficial, and therapies such as cytokine storm inhibitors and monoclonal antibodies were also not effective and require further investigation. CONCLUSIONS: There is no single therapy effective against COVID-19. However, a combination of therapies administered at different stages of infection may provide some benefit. This conclusion is reflected in the limited effects of these treatments in previous human coronaviruses.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and adrenal cortex: 1
    • abdominal pain vomiting and acute ards respiratory distress syndrome: 1
    • abdominal pain vomiting and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain vomiting and adrenal cortex: 1
    • abdominal pain vomiting cause and acute respiratory syndrome: 1, 2
    • acute ards respiratory distress syndrome and add benefit: 1
    • acute ards respiratory distress syndrome and administration timing: 1
    • acute ards respiratory distress syndrome and long hospitalization: 1
    • acute respiratory syndrome and add benefit: 1, 2, 3
    • acute respiratory syndrome and additional reference: 1, 2, 3, 4, 5
    • acute respiratory syndrome and administration timing: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory syndrome and adrenal cortex: 1
    • acute respiratory syndrome and long hospitalization: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14